Protagonist Therapeutics, Inc. (PTGX) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders.
Is Protagonist Therapeutics, Inc. stock overvalued or undervalued in 2026?
Protagonist Therapeutics, Inc. (PTGX) trades at 140× earnings (P/E). No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Protagonist Therapeutics, Inc.
Market cap $9B · 52 weeks $76 – $159 (9 % below the high) · P/E 140× · Dividend none · Next earnings November 5, 2026 · expected EPS $2.50 · Closing price, Oct 30 · accounts published Aug 5.
- Valuation: P/Sales 79.5× (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 5 of 8 (uneven).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 1.7 %, fails.
- Market cap / Cash 16.2×, fails.
- Annual cash burn $0.91, passes.
- Total Debt 0.0×, passes.
Against its peers (reference peers) — Protagonist Therapeutics, Inc.: P/E 140×; EV/EBITDA 104×; ROIC 6.7 %; $9.4B. TG Therapeutics, Inc. (P/E 22.3×; EV/EBITDA 71.8×; ROIC 9.9 %; $9.4B), Caris Life Sciences, Inc. (P/E 95.9×; EV/EBITDA 54.8×; ROIC 14.7 %; $9.7B), Krystal Biotech, Inc. (P/E 41.6×; EV/EBITDA 42.8×; ROIC 14.4 %; $9.8B).
Profitability
| Return on Equity | 12.03% |
| Return on Invested Capital | 6.74% |
| Return on Assets | 9.36% |
| Gross Margin | 99.86% |
| Operating Margin | 20.69% |
| Net Margin | 29.40% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 21.71 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 59.63 |
Price Performance
| 1 month | +3.42% |
| 3 months | +6.66% |
| Year-to-date | +65.85% |
| 1 year | +84.24% |
| 3 years | +769.97% |
| 5 years | +339.87% |
| 10 years | +692.83% |
Related companies: IMVT · SYRE · IRON · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L
Explore sector: Healthcare · Biotechnology
More sections of PTGX: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks